Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Updates in Hodgkin’s and non-Hodgkin lymphomas

ASCO Direct Highlights™ Miami 2021 Symposium

9 - 10 Jul 2021

Published: 30 Jul 2021

Views: 580

Rating:

Save

Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA

Dr Jose Sandoval-Sus speaks to ecancer about Hodgkin's and non-Hodgkin lymphomas at the ASCO Direct Highlights Miami Symposium 2021.

He discusses various studies that were presented at the meeting including ELEVATE-RR, the fixed-duration aspect of the phase II CAPTIVATE study, ECOG-ACRIN E1411 and CALGB 50801.

Watch the meeting in full by following the links below:

Related Videos

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

More from ecancer